Now showing items 1-6 of 6

    • Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. 

      Austin, S; Bali, Deeksha Sarihyan; Buckley, Anne Frances; Case, Laura Elizabeth; Kishnani, Priya Sunil; Koeberl, Dwight D; Smith, Edward; ... (8 authors) (FASEB J, 2014-05)
      Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) ...
    • Bioluminescence imaging of glucose in tissue surrounding polyurethane and glucose sensor implants. 

      Klitzman, Bruce; Prichard, HL; Reichert, WM; Schroeder, T (J Diabetes Sci Technol, 2010-09-01)
      BACKGROUND: The bioluminescence technique was used to quantify the local glucose concentration in the tissue surrounding subcutaneously implanted polyurethane material and surrounding glucose sensors. In addition, some implants ...
    • FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. 

      Grabner, Alexander; Wolf, Myles; Schramm, Karla; Silswal, Neerupma; Hendrix, Matt; Yanucil, Christopher; Czaya, Brian; ... (14 authors) (Scientific reports, 2017-05-16)
      Fibroblast growth factor (FGF) 23 is a phosphaturic hormone that directly targets cardiac myocytes via FGF receptor (FGFR) 4 thereby inducing hypertrophic myocyte growth and the development of left ventricular hypertrophy ...
    • Interleukin-15 receptor blockade in non-human primate kidney transplantation. 

      Faure, JP; Fechner, J; Haustein, S; Kayaoglu, A; Knechtle, Stuart J; Kwun, J; Roenneburg, D; ... (8 authors) (Transplantation, 2010-04-27)
      BACKGROUND: Interleukin (IL)-15 is a chemotactic factor to T cells. It induces proliferation and promotes survival of activated T cells. IL-15 receptor blockade in mouse cardiac and islet allotransplant models has led to ...
    • Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. 

      Young, Ken; Xia, Y; Xu-Monette, ZY; Tzankov, A; Li, X; Manyam, GC; Murty, V; ... (33 authors) (Leukemia, 2017-03)
      PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and ...
    • Prostate biopsy in selecting candidates for hemiablative focal therapy. 

      Hruza, M; Mouraviev, V; Polascik, Thomas J; Rassweiler, J; Tsivian, M (J Endourol, 2010-05)
      Focal therapy (FT) for the management of clinically localized prostate cancer (PCa) is growing from a concept to reality because of increased interest of both patients and physicians. Selection protocols, however, are yet ...